Targeting Mutant p53 in Human Tumors
The DOI matches its Crossref record; 12 of the 12 references it cites were found in a registry or an index.
Abstract
Article Tools UNDERSTANDING THE PATHWAY Article Tools OPTIONS & TOOLS Export Citation Track Citation Add To Favorites Rights & Permissions COMPANION ARTICLES No companion articles ARTICLE CITATION DOI: 10.1200/JCO.2012.44.0412 Journal of Clinical Oncology - published online before print September 10, 2012 PMID: 22965952 Targeting Mutant p53 in Human Tumors Brian D. LehmannxBrian D. LehmannSearch for articles by this author , Jennifer A. PietenpolxJennifer A. PietenpolSearch for articles by this author Show More Vanderbilt University School of Medicine, Nashville, TN https://doi.org/10.1200/JCO.2012.44.0412 First Page Full Text PDF Figures and Tables © 2012 by American Society of Clinical Oncology
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Momand, J., Zambetti, G. P., Olson, D. C., George, D., & Levine, A. J. (1992) · Cell · doi:10.1016/0092-8674(92)90644-r · Cited by 3,113
When mutants gain new powers: News from the mutant p53 field
Brosh, R., & Rotter, V. (2009) · Nature Reviews Cancer · doi:10.1038/nrc2693 · Cited by 1,132
Restoration of the tumor suppressor function to mutant p53 by a low-molecular-weight compound
Bykov, V. J. N., Issaeva, N., Shilov, A., Hultcrantz, M., Pugacheva, E., Chumakov, P., Bergman, J., Wiman, K. G., & Selivanova, G. (2002) · Nature Medicine · doi:10.1038/nm0302-282 · Cited by 1,067
Shangary, S., Qin, D., McEachern, D., Liu, M., Miller, R. S., Qiu, S., Nikolovska-Coleska, Z., Ding, K., Wang, G., Chen, J., et al. (2008) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0708917105 · Cited by 660
PRIMA-1 reactivates mutant p53 by covalent binding to the core domain
Lambert, J. M. R., Gorzov, P., Veprintsev, D. B., Söderqvist, M., Segerbäck, D., Bergman, J., Fersht, A. R., Hainaut, P., Wiman, K. G., & Bykov, V. J. N. (2009) · Cancer Cell · doi:10.1016/j.ccr.2009.03.003 · Cited by 592
Gain of function of mutant p53 by coaggregation with multiple tumor suppressors
Xu, J., Reumers, J., Couceiro, J. R., De Smet, F., Gallardo, R., Rudyak, S., Cornelis, A., Rozenski, J., Zwolinska, A., Marine, J.-C., et al. (2011) · Nature Chemical Biology · doi:10.1038/nchembio.546 · Cited by 543
Lehmann, S., Bykov, V. J. N., Ali, D., Andrén, O., Cherif, H., Tidefelt, U., Uggla, B., Yachnin, J., Juliusson, G., Moshfegh, A., et al. (2012) · Journal of Clinical Oncology · doi:10.1200/jco.2011.40.7783 · Cited by 406
Targeted rescue of a destabilized mutant of p53 by an in silico screened drug
Boeckler, F. M., Joerger, A. C., Jaggi, G., Rutherford, T. J., Veprintsev, D. B., & Fersht, A. R. (2008) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0805326105 · Cited by 387
Translating p53 into the clinic
Cheok, C. F., Verma, C. S., Baselga, J., & Lane, D. P. (2011) · Nature Reviews Clinical Oncology · doi:10.1038/nrclinonc.2010.174 · Cited by 381
PRIMA-1MET synergizes with cisplatin to induce tumor cell apoptosis
Bykov, V. J. N., Zache, N., Stridh, H., Westman, J., Bergman, J., Selivanova, G., & Wiman, K. G. (2005) · Oncogene · doi:10.1038/sj.onc.1208419 · Cited by 252
Research works printed but not linked: 17
- 10.1002/path.2784 · DOI · Paper page
- 10.1101/gad.181685.111 · DOI · Paper page
- 10.1016/S1535-6108(03)00081-3 · DOI
- 10.1038/embor.2012.74 · DOI · Paper page
- Riemenschneider MJ, 1999, Cancer Res, 59, 6091
- Esteller M, 2000, Cancer Res, 60, 129
- 10.1126/science.1092472 · DOI · Paper page
- 10.1074/jbc.274.49.34924 · DOI · Paper page
- 10.1038/nm1146 · DOI · Paper page
- 10.4161/cc.9.6.10956 · DOI · Paper page
- 10.1073/pnas.0607286103 · DOI · Paper page
- 10.1016/j.ccr.2012.03.042 · DOI · Paper page
- 10.1126/science.286.5449.2507 · DOI · Paper page
- 10.1074/jbc.M109.083469 · DOI · Paper page
- 10.1074/jbc.M501664200 · DOI · Paper page
- 10.1016/j.molonc.2008.02.004 · DOI · Paper page
- 10.1038/sj.onc.1205362 · DOI · Paper page
Cited by
Mutant p53 in Cancer: New Functions and Therapeutic Opportunities
Muller, P. A. J., & Vousden, K. H. (2014) · Cancer Cell · doi:10.1016/j.ccr.2014.01.021 · Cited by 1,545
“…et al., 2002 M246I H23 endogenous Vaughan et al., 2012b R248W, D281G 10(3) stable/transient Loging and Reisman, 1999; Scian et al., 2004a R249S KNS-62 endogenous Vaughan et al., 2012a R267P H1437 endogenous Vaughan et al., 2012a; Vaughan et al., 2012b R273C H1048 endogenous Vaughan et al., 2012b”
BackgroundLehmann, B. D., & Pietenpol, J. A. (2014) · The Journal of Pathology · doi:10.1002/path.4280 · Cited by 495
Self-citationMutant p53 Drives Pancreatic Cancer Metastasis through Cell-Autonomous PDGF Receptor β Signaling
Weissmueller, S., Manchado, E., Saborowski, M., Morris, J. P., Wagenblast, E., Davis, C. A., Moon, S.-H., Pfister, N. T., Tschaharganeh, D. F., Kitzing, T., et al. (2014) · Cell · doi:10.1016/j.cell.2014.01.066 · Cited by 466
“However, mutant p53 is neither a targetable cell-surface protein nor a druggable enzyme (Levine and Oren, 2009), and novel therapeutic modalities, such as RNAi or restoring wild-type p53 conformations, have yet to show efficacy in clinical studies (Lehmann and Pietenpol, 2012).”
The p53 Pathway in Glioblastoma
Zhang, Y., Dube, C., Gibert, M., Cruickshanks, N., Wang, B., Coughlan, M., Yang, Y., Setiady, I., Deveau, C., Saoud, K., et al. (2018) · Cancers · doi:10.3390/cancers10090297 · Cited by 440
Mutant p53 in Cancer: Accumulation, Gain-of-Function, and Therapy
Yue, X., Zhao, Y., Xu, Y., Zheng, M., Feng, Z., & Hu, W. (2017) · Journal of Molecular Biology · doi:10.1016/j.jmb.2017.03.030 · Cited by 308
“Currently, PRIMA-1 has shown a favorable safety profile in phase I clinical trials, and APR-246 has entered a phase II clinical trial [117,121,122].”
BackgroundCollateral lethality: a new therapeutic strategy in oncology
Muller, F. L., Aquilanti, E. A., & DePinho, R. A. (2015) · Trends in Cancer · doi:10.1016/j.trecan.2015.10.002 · Cited by 132
“Other examples of recurrent homozygous loci include 18q21 (SMAD4) and 1p36 (Several TSG).”
BackgroundHaffo, L., Lu, J., Bykov, V. J. N., Martin, S. S., Ren, X., Coppo, L., Wiman, K. G., & Holmgren, A. (2018) · Scientific Reports · doi:10.1038/s41598-018-31048-7 · Cited by 73
Metadata
- Authors
- Lehmann, B. D., & Pietenpol, J. A.
- Venue
- Journal of Clinical Oncology
- Published
- 2012-10-10
- Volume
- 30
- Issue
- 29
- Pages
- 3648-3650
- ISSN
- 0732-183X (ISSN-L)
- 1527-7755
- OpenAlex
- W2025494132
- Cited by
- 72
- References
- 12
- FWCI
- 4.26
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.